4.5 Billion Molecules, One Mission: Cure the ‘Undruggable’ Diseases

Why Every Medical Affairs Team Needs Their Own AI Agent in 2025

Medical misinformation, life sciences burnout, and AI-powered content creation collide in this episode with Dr. Ome Ogbru, founder & CEO of AINGENS and creator of MACg (Medical Affairs Content Generator).  Learn how AI in biotech is tackling the complexities of medical affairs—from literature review and content automation to compliance and regulatory writing. ⚡️ WHAT YOU’LL LEARN: - Why medical affairs and regulatory teams can’t rely on ChatGPT alone. - How MACg integrates real‑time PubMed search, citation generation, and secured collaboration to streamline scientific writing  - Why MACg users report up to 50 % faster writing and 50–70 % faster medical-legal review. - Why AI platforms like MACg must be purpose-built for life sciences (GDPR & SOC 2 compliant). - What is “human-in-the-loop” AI workflow—and how it balances automation and review to maintain accuracy and trust. - Real-world use cases: scientific summaries, medical info letters and more. 🎙️ Guest: Ome Ogbru | Founder and President of AINGENS [https://aingens.com/] 🔗 Connect with Ome: LinkedIn [https://www.linkedin.com/in/ome-ogbru-pharmd/] For transcripts, check out the podcast website - www.lifesciencespod.com [https://www.lifesciencespod.com/]

VC Money Tight? Here’s How Startups Still Land Top Talent (2025)

What happens when 3,500 staffers lose their jobs due to FDA layoffs, venture capital (VC) term sheets shrink, and AI drug-discovery startups raise $600 million rounds?  Executive recruiter William Holodnak (ex-Fidelity, global biotech headhunter) breaks down 2025’s wild hiring market—and how founders can still build A-teams. In this episode you’ll learn: - Why the April-1 FDA layoffs could delay approvals—and open new career doors for ex-regulators.  - The three traits VCs demand in first-time biotech CEOs during a funding slump.  - How AI-driven platforms like Isomorphic Labs raised mega-rounds in a down market.  - Immunology’s surge and why oncology startups are pivoting.  - Board-level recruiting tactics that de-risk your Series B. 🎙️ Guest: William Holodnak | Founder and President of Occam Global [https://www.occam-global.com/] 🔗 Connect with Bill: LinkedIn [https://www.linkedin.com/in/williamholodnak/] 📌 Chapters: 00:00 Intro 05:45 Cambridge—“the Florence of Biotech” origin story 08:20 FDA layoffs: threat or opportunity? 13:30 Biotech venture capital mood swings & funding checkpoints 18:00 What VCs really screen for in scientific founders 25:05 The “horses for courses” CEO model explained 33:00 Hot therapeutic areas: AI drug discovery, immunology, repurposing 38:30 Why boards need operators, not just investors 47:00 Career improvisation: William’s closing advice For transcripts, check out the podcast website - www.lifesciencespod.com [https://www.lifesciencespod.com/]

Why Most Healthcare Brands Fail (And How to Fix It)

Why Most Healthcare Brands Fail (And How to Fix It) In this episode, Holley Miller, Founder and President of Grey Matter Marketing, reveals why most medtech and life sciences companies fail to connect with their audience—and how to fix that with brand clarity and strategic storytelling. You’ll learn how marketing in regulated industries is evolving, why flashy tactics often fall flat, and how brand equity is built through consistency, credibility, and emotional connection. Holley also shares lessons from working with emerging startups and large enterprises, offering a strategy for aligning commercial goals with patient and provider trust. 🎙️ Guest: Holley Miller | Founder and President of Grey Matter Marketing [https://www.greymattermarketing.com/] 🔗 Connect with Holley: LinkedIn [https://www.linkedin.com/in/holleymalia/] 📌 Chapters: 00:00 The Journey of Grey Matter: 19 Years in Life Science Marketing 02:45 Evolution of Marketing in Life Sciences 05:59 Category Design: Creating and Owning a Market 08:54 Understanding Problems: The Key to Category Creation 12:02 Building the Right Team for Success 14:57 Painkillers vs. Vitamins: Motivating Change in Healthcare 27:30 Life Sciences Market Domination Framework 34:27 The Four Pillars of Market Success 42:31 Market Domination Scorecard: Assessing Your Strategy 45:09 What Matters: The Impact of Your Work 48:39 Finding Your Superpower Subscribe for more insights on the latest in Life Sciences! For transcripts, check out the podcast website - www.lifesciencespod.com [https://www.lifesciencespod.com/]

4.5 Billion Molecules, One Mission: Cure the ‘Undruggable’ Diseases

Solving the “Undruggable” Disease Problem with Goldilocks Molecules In this episode, Christian Schafmeister, Founder and President of Third Law Molecular, reveals a new class of therapeutics designed to target what most consider “undruggable” diseases—conditions like Alzheimer’s, certain cancers, and rare genetic disorders. Christian explains the science behind spiroligomers—modular, mid-sized molecules that act like molecular LEGOs, offering the perfect balance between small molecules and biologics. Learn how his team created a library of 4.5 billion molecules and what makes these structures uniquely suited to bind difficult protein targets, including disordered proteins and intracellular surfaces. We also talk about the Goldilocks Zone of drug design, how Third Law’s chemistry was born out of academic and defense-backed research, and why the future of drug discovery may lie in designing therapeutics that are just right. 🎙️ Guest: Christian Schafmeister | Founder and President at ThirdLaw Molecular 🔗 Connect with Christian: LinkedIn [https://www.linkedin.com/in/christian-schafmeister-5261a225/] 🔗 ThirdLaw Molecular Website [https://thirdlawtx.com/] 🔗 Spiroligomers Presentation [https://www.youtube.com/watch?v=-gex8pUHJNk] 📌 Chapters: 00:00 Introduction to Undruggable Diseases 01:30 Discovering Spiroligomers: A New Class of Molecules 08:04 Challenges in Targeted Drug Discovery 09:31 Building a Library of Molecules 14:47 The Birth of Third Law Molecular 17:19 The Goldilocks Molecule Concept 19:56 Applications in Cancer and Other Diseases 21:24 Collaborations with Big Pharma 23:39 Handling Clinical Trials 27:20 Future Directions and Industry Insights Subscribe for more insights on the latest in Life Sciences! For transcripts, check out the podcast website - www.lifesciencespod.com [https://www.lifesciencespod.com/]

What Separates Life Science Startup Winners from Losers?

Why Startups Fail (Hint: It’s Not the Innovation) In this episode, Carlo Odicino, CEO and Founder at One TEAM Partners, shares the real reasons why most early-stage life sciences companies struggle to survive—and it has nothing to do with bad science. Learn the hidden pitfalls of scaling too fast, confusing innovation with execution, and chasing too many priorities at once. Carlo offers practical strategies for building focus, setting boundaries, and creating a people-first culture that actually scales. You’ll also learn why execution beats experimentation when commercial success is the goal—and how to stay aligned with investors without over-promising. This conversation is packed with actionable advice for startup leaders, biotech founders, and anyone facing the complexities of early-stage growth. 🎙️ Guest: Carlo Odicino | CEO and Founder at One TEAM Partners 🔗 Connect with Carlo: LinkedIn [https://www.linkedin.com/in/cjodicino/] 🔗 One Team Partners Website [https://oneteampartners.com/] 📌 Chapters: 00:00 The Innovation-Execution Tension 07:30 Managing Investor Expectations 17:48 Establishing Core Values in Organizations 24:56 Work-Life Integration vs. Balance 35:11 The Role of Human Connection in Innovation Subscribe for more insights on the latest in Life Sciences! For transcripts, check out the podcast website - www.lifesciencespod.com [https://www.lifesciencespod.com/]